Clinical Trial Update: Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing bevacizumab to Pulvis Talci for malignant pleural effusion. Current status of the trial is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Effusion

Drugs mentioned

• Bevacizumab (bevacizumab)
• Pulvis Talci (Pulvis Talci)

Snippet

Sponsor: Tang-Du Hospital | Conditions: Malignant Pleural Effusion | Phase 2 | Status: UNKNOWN